DUNAD Therapeutics Emerges to Develop Next-Generation Small Molecule Therapeutics Based on First Tuneable Targeted Protein Degradation Technology
March 23, 2021
New UK company backed by Epidarex Capital emerges from stealth Cambridge, UK, March 23, 2021 – Dunad Therapeutics (“Dunad”) emerges today to develop next-generation small